Seeking Alpha

Mike Havrilla » Comments » ACUS

  • 12 Extreme FDA Trades on New Product Decisions [View article]
    The upcoming FDA panel meeting will be key (6/2/09) and if it gets a positive review and rec for approval the stock could easily trade above your cost basis. However, the FDA has been tough on approving new antibiotics or even expanding the label of already approved anti-infectives over the past year so it makes for a high risk/reward trade going into the panel meeting.


    On Apr 13 08:57 PM godfreta wrote:

    > What do you think about adls. I have been holding now for three years.
    > I am dying here. My cost average is about .69 cents. Ihave 50% of
    > my savings in this company. I am physician and i CAN NOT IMAGINE
    > it failing.
    Apr 14 05:06 am |Rating: 0 0 |Link to Comment
  • 12 Extreme FDA Trades on New Product Decisions [View article]
    CTIC did not submit the pixantrone NDA yet:
    biomedreports.com/arti...


    On Apr 09 06:36 PM Earl who likes seeking alpha wrote:

    > You missed a major one in my opinion. CTIC, who you did mention,
    > sold their share of Zevalin in order to help cashflow for the rest
    > of the year. CTIC has pixantrone, a chemotherapy drug, which has
    > the potential to exceed Rituximab (currently a $5 bil a year drug).
    Apr 09 20:18 pm |Rating: 0 0 |Link to Comment
More on ACUS by Mike Havrilla
Comments by Ticker
AAWW, ABIO, ABMD, ABT, ABX, ACAD, ACCP.OB, ACHN, ACLI, ACOR, ACTC.PK, ACUR, ACUS, ADLR, ADLS, ADLS.OB, AEZS, AFFX, AGEN, AGF, AGN, AHBIF.PK, AIQ, AIS, ALEX, ALGT, ALKS, ALO, ALPMF.PK, ALTH, ALV, ALVR, AMAG, AMGN, AMR, AMX, ANDS, ANPI, APPA, APPX, ARDM.OB, ARIA, ARKTF.PK, ARNA, ARQL, ARYX, ASO, ASTM, ATHX, ATSI,
Mike Havrilla's
Comments Stats
172 comments
Rating: 27 (48 - 21 )